American Journal of Cancer

, Volume 5, Issue 6, pp 357–362 | Cite as

Cyclo-Oxygenase-2 Inhibitors in Colorectal Cancer Prevention

  • Menachetn Moshkowitz
  • Nadir Arber
Leading Article


Previous experimental epidemiologic and clinical studies have shown a significant reduction in colorectal cancer occurrence and mortality among individuals taking NSAIDs. NSAIDs inhibit the enzymatic activity of both isoforms of cyclo-oxy genase (COX-1 and COX-2), which regulate prostaglandin synthesis. COX-2 is an inducible enzyme that is overexpressed at sites of inflammation and in several epithelial cancers. Several studies have indicated that COX-2 overexpression appears to be involved in tumorigenesis by promoting cell division and proliferation, inhibiting apoptosls, stimulating anglogenesls, altering cell adhesion, and enhancing tumor cell invasiveness. Blocking of these activities by COX-2 selective inhibitors is considered the main mechanism that explains the anticarcinogenic effect of COX-2 selective Inhibitors. In addition, other independent COX-2 mechanisms have been described.

Treatment with selective COX-2 inhibitors has shown promising results In the suppression of colon polyps, both in animal models for familial adenomatous polyposis (FAP) and in patients with FAP, and recent clinical studies have Identified the potential benefit of these agents for colon cancer chemopreventlon. However, serious concerns have been raised regarding the potential adverse effects of long-term selective COX-2 inhibitor use, most notably those within the cardiovascular system, such as myocardial Infarctions, strokes, and increased blood pressure.

The role of COX-2 inhibitors in cancer chemopreventlon is still evolving and a careful risk/benefit analysis of the recent clinical studies would mandate the precise clinical setting that these drags can be used in.


Adenoma Curcumin Celecoxib Familial Adenomatous Polyposis Rofecoxib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



N. Arber has performed consultancies for G.I. View Ltd, Israel, owns stock and has received honoria from Pfizer, USA, and has received grants from Pfizer, USA and Merck, USA. No sources of funding were used to assist in the preparation of this review.


  1. 1.
    American Cancer Society. Cancer facts & figures 2005 [online]. Available from URL: [Accessed 2006 Nov 16]
  2. 2.
    Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95(17): 1276–99PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett A, Del Tacca M. Proceedings: prostaglandins in human colonic carcinoma. Gut 1975; 16: 409PubMedGoogle Scholar
  4. 4.
    Jaffe BM. Prostaglandins and cancer: an update. Prostaglandins 1974; 6: 453–61PubMedGoogle Scholar
  5. 5.
    Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58(8): 1750–3PubMedGoogle Scholar
  6. 6.
    Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111(4): 1134–40PubMedCrossRefGoogle Scholar
  7. 7.
    DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110(4): 1259–62PubMedCrossRefGoogle Scholar
  8. 8.
    Thun MJ, Namboodiri MM, Heath Jr CJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6PubMedCrossRefGoogle Scholar
  9. 9.
    Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138–46PubMedCrossRefGoogle Scholar
  10. 10.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–9PubMedGoogle Scholar
  11. 11.
    Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–14PubMedCrossRefGoogle Scholar
  12. 12.
    Arber N. Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 2000; 14: 299–307PubMedGoogle Scholar
  13. 13.
    Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004; 4(1): 29–42PubMedCrossRefGoogle Scholar
  14. 14.
    Kelloff G. Chemoprevention of colorectal cancer. In: Young G, Rozen P, Levin B, editors. Prevention and early detection of colorectal cancer. New York: W.B. Saunders, 1996: 116–39Google Scholar
  15. 15.
    FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42PubMedCrossRefGoogle Scholar
  16. 16.
    Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplasic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999; 190: 445–50PubMedCrossRefGoogle Scholar
  17. 17.
    Hao XP, Bishop AE, Wallace MH, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187: 295–301PubMedCrossRefGoogle Scholar
  18. 18.
    Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61(4): 1733–40PubMedGoogle Scholar
  19. 19.
    Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002; 62: 28–32PubMedGoogle Scholar
  20. 20.
    Afford S, Randhawa S. Apoptosis. Mol Pathol 2000; 53: 55–63PubMedCrossRefGoogle Scholar
  21. 21.
    Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996; 93: 7950–4PubMedCrossRefGoogle Scholar
  22. 22.
    Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811–6PubMedGoogle Scholar
  23. 23.
    Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83(3): 493–501PubMedCrossRefGoogle Scholar
  24. 24.
    Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225–31PubMedCrossRefGoogle Scholar
  25. 25.
    Samaha H, Kelloff G, Steele V, et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57: 1301–5PubMedGoogle Scholar
  26. 26.
    Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767–72PubMedGoogle Scholar
  27. 27.
    Ganswindt U, Budach W, Jendrossek V, et al. Combination of celecoxib with percutaneous radiotherapy in patients with localized prostate cancer: a phase I study [abstract]. Radiat Oncol 2006; 1: 9PubMedCrossRefGoogle Scholar
  28. 28.
    Liao Z, Komaki R, Milas L, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005; 11(9): 3342–8PubMedCrossRefGoogle Scholar
  29. 29.
    Shiff SJ, Koutsos MI, Qiao L, et al. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179–88PubMedCrossRefGoogle Scholar
  30. 30.
    Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8PubMedGoogle Scholar
  31. 31.
    Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823–6PubMedGoogle Scholar
  32. 32.
    Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–16PubMedCrossRefGoogle Scholar
  33. 33.
    Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11PubMedGoogle Scholar
  34. 34.
    Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589–94PubMedCrossRefGoogle Scholar
  35. 35.
    Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94(7): 3336–40PubMedCrossRefGoogle Scholar
  36. 36.
    Yao M, Lam EC, Kelly CR, et al. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004; 90(3): 712–9PubMedCrossRefGoogle Scholar
  37. 37.
    Fogel-Petrovic M, Long JA, Knight DA, et al. Activated human dendritic cells express inducible cyclo-oxygenase and synthesize prostaglandin E2 but not prostaglandin D2. Immunol Cell Biol 2004; 82(1): 47–54PubMedCrossRefGoogle Scholar
  38. 38.
    Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57(14): 2909–15PubMedGoogle Scholar
  39. 39.
    Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52(2): 237–45PubMedCrossRefGoogle Scholar
  40. 40.
    Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006; 98(11): 736–47PubMedCrossRefGoogle Scholar
  41. 41.
    Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274(38): 27307–14PubMedCrossRefGoogle Scholar
  42. 42.
    Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of perox-isome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A, 2000; 97(24): 13275–80PubMedCrossRefGoogle Scholar
  43. 43.
    He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drags. Cell 1999; 99(3): 335–45PubMedCrossRefGoogle Scholar
  44. 44.
    Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control result from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399–404PubMedGoogle Scholar
  45. 45.
    Montoya RG, Wargovich MJ. Chemoprevention of gastrointestinal cancer. Cancer Metastasis Rev 1997; 16: 405–19PubMedCrossRefGoogle Scholar
  46. 46.
    Thun MJ. NSAIDs use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996; 25: 333–47PubMedCrossRefGoogle Scholar
  47. 47.
    Greenberg ER, Baron JA, Freeman DHJ, et al. Reduced risk of large-bowel adenomas among aspirin users: the Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85: 912–6PubMedCrossRefGoogle Scholar
  48. 48.
    Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992–8PubMedCrossRefGoogle Scholar
  49. 49.
    Sheng H, Shao J, Kirkland SC. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–9PubMedCrossRefGoogle Scholar
  50. 50.
    Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566–71PubMedGoogle Scholar
  51. 51.
    Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83–7PubMedCrossRefGoogle Scholar
  52. 52.
    Arber N, Strul H. Non-steroidal anti-inflammatory drags and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. Isr Med Assoc J 2000; 2: 695–702PubMedGoogle Scholar
  53. 53.
    Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drags and risk of colorectal cancer. JAMA 2005; 294(8): 914–23PubMedCrossRefGoogle Scholar
  54. 54.
    Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12(1): 88–93PubMedCrossRefGoogle Scholar
  55. 55.
    Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drags and incidence of colorectal cancer. Arch Intern Med 1999; 159: 161–6PubMedCrossRefGoogle Scholar
  56. 56.
    Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000; 11(4): 376–81CrossRefGoogle Scholar
  57. 57.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–52PubMedCrossRefGoogle Scholar
  58. 58.
    Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003; 48: 1998–2002PubMedCrossRefGoogle Scholar
  59. 59.
    Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102PubMedCrossRefGoogle Scholar
  60. 60.
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80PubMedCrossRefGoogle Scholar
  61. 61.
    Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355(9): 873–84PubMedCrossRefGoogle Scholar
  62. 62.
    Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355(9): 885–95PubMedCrossRefGoogle Scholar
  63. 63.
    Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352(11): 1081–91PubMedCrossRefGoogle Scholar
  64. 64.
    Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296(13): 1619–32PubMedCrossRefGoogle Scholar
  65. 65.
    Lev-Ari S, Strier L, Kazanov D. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11(18): 6738–44PubMedCrossRefGoogle Scholar
  66. 66.
    Lev-Ari S, Zinger H, Kazanov D, et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in pancreatic adeno-carcinoma cells. Biomed Pharmacother 2005Oct; 59Suppl. 2: S276–80PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Integrated Cancer Prevention CenterTel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv UniversityTel AvivIsrael

Personalised recommendations